Avoiding misdiagnosis: Expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner

73Citations
Citations of this article
109Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Transthyretin amyloidosis (also known as ATTR amyloidosis) is a systemic, life-threatening disease characterized by transthyretin (TTR) fibril deposition in organs and tissue. A definitive diagnosis of ATTR amyloidosis is often a challenge, in large part because of its heterogeneous presentation. Although ATTR amyloidosis was previously considered untreatable, disease-modifying therapies for the treatment of this disease have recently become available. This article aims to raise awareness of the initial symptoms of ATTR amyloidosis among general practitioners to facilitate identification of a patient with suspicious signs and symptoms. Methods: These consensus recommendations for the suspicion and diagnosis of ATTR amyloidosis were developed through a series of development and review cycles by an international working group comprising key amyloidosis specialists. This working group met to discuss the barriers to early and accurate diagnosis of ATTR amyloidosis and develop a consensus recommendation through a thorough search of the literature performed using PubMed Central. Results: The cardiac and peripheral nervous systems are most frequently involved in ATTR amyloidosis; however, many patients often also experience gastrointestinal and other systemic manifestations. Given the multisystemic nature of symptoms, ATTR amyloidosis is often misdiagnosed as a more common disorder, leading to significant delays in the initiation of treatment. Although histologic evaluation has been the gold standard to confirm ATTR amyloidosis, a range of tools are available that can facilitate early and accurate diagnosis. Of importance, genetic testing should be considered early in the evaluation of a patient with unexplained peripheral neuropathy. Conclusions: A diagnostic algorithm based on initial red flag symptoms and manifestations of cardiac or neurologic involvement will facilitate identification by the general practitioner of a patient with clinically suspicious symptoms, enabling subsequent referral of the patient to a multidisciplinary specialized medical center.

References Powered by Scopus

Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis

2172Citations
N/AReaders
Get full text

Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy

1847Citations
N/AReaders
Get full text

Nonbiopsy diagnosis of cardiac transthyretin amyloidosis

1490Citations
N/AReaders
Get full text

Cited by Powered by Scopus

2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee

230Citations
N/AReaders
Get full text

Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness

52Citations
N/AReaders
Get full text

The neuropathy in hereditary transthyretin amyloidosis: A narrative review

47Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Gertz, M., Adams, D., Ando, Y., Beirão, J. M., Bokhari, S., Coelho, T., … Merlini, G. (2020). Avoiding misdiagnosis: Expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Family Practice, 21(1). https://doi.org/10.1186/s12875-020-01252-4

Readers' Seniority

Tooltip

Researcher 16

48%

PhD / Post grad / Masters / Doc 9

27%

Professor / Associate Prof. 7

21%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 34

74%

Biochemistry, Genetics and Molecular Bi... 5

11%

Social Sciences 4

9%

Pharmacology, Toxicology and Pharmaceut... 3

7%

Article Metrics

Tooltip
Mentions
News Mentions: 1
Social Media
Shares, Likes & Comments: 1

Save time finding and organizing research with Mendeley

Sign up for free